Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – CNS tumours

3522 - Precision medicine for patients with primary brain tumors: Molecular Screening for Cancer Treatment Optimization (MOSCATO) prospective trial

Date

28 Sep 2019

Session

Poster Discussion – CNS tumours

Presenters

Wafa Boulfoul

Citation

Annals of Oncology (2019) 30 (suppl_5): v143-v158. 10.1093/annonc/mdz243

Authors

W. Boulfoul1, C. Baldini2, I. Borget3, P. Martin Romano4, L. Verlingue5, L. Lacroix6, E. Angevin7, E. Rouleau8, A. Varga9, S. Postel Vinay10, A. Gazzah11, R. Bahleda1, A. Marabelle5, V. Ribrag10, P. Vuagnat12, S. Champiat13, J. Michot14, A. Hollebecque9, J. Soria15, C. Massard1

Author affiliations

  • 1 Ditep, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 2 Drug Development Department, Gustave Roussy, 94800 - villejuif/FR
  • 3 Biostatistics, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 4 Medical Oncology, Gustave Roussy, 94805 - Villejuif/FR
  • 5 Drug Development Department, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 6 Department Of Medical Biology And Pathology, Laboratory Of Translational Research And Biological Resource Center, Ammica, Inserm Us23/cnrs Ums3655, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 7 Drug Development Department (ditep), Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 8 Genetics, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 9 Ditep, Gustave Roussy, 94805 - Villejuif/FR
  • 10 Ditep, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 11 Department Of Drug Development (ditep), Gustave Roussy, Université Paris-Saclay, 94800 - Villejuif/FR
  • 12 Ditep - Département D'innovation Thérapeutique Et D’essais Précoces, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 13 Drug Development Department (ditep), Gustave Roussy, 94805 - Villejuif/FR
  • 14 Drug Developpement Department, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 15 Early Drugs, Medimmune, 20878 - Gaithersburg/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3522

Background

Primary brain tumors are highly heterogeneous and current therapy confers only modest clinical benefit. There is a tremendous need for new therapeutic options and genomic profiling could help defining new strategies.

Methods

Data from patients with advanced primary brain tumors enrolled in the prospective clinical trial MOSCATO at the Drug Development Department (DITEP) at Gustave Roussy Cancer Center were retrospectively reviewed. Multiple high throughput molecular techniques were used to identify genetic mutations: Next Generation Sequencing (NGS), comparative genomic hybridization array (CGHa) and Foundation one CDx (FMI). Matched therapy was decided accordingly for patients who had targeted molecular alterations.

Results

Between April 2016 and December 2018, 103 patients with primary brain tumors were enrolled. Median age was 48 years (range, 19-75), median number of previous systemic therapies was 2 (range, 0–5), 98% had an ECOG performance status 0 or 1. The most prevalent histology was glioblastoma (70 %). Ten patients were screen failure due to unavailability of tumor tissue and no possibility of new brain biopsy. Eighty-nine molecular analyses were successful (CGH: N = 45, NGS: N = 47, FMI: N = 42). Median time between consent and results was 49 days (range, 18-235). Tumor mutational burden (TMB) was available in 42 pts and was considered low (<6) in 33 patients. Altogether, 365 actionable alterations were detected: amplification (n = 82; 22.5 %), deletion (n = 76; 21%), mutation (n = 197; 54 %) and rearrangement (n = 10 ; 2.7 %). Most frequent alterations were: CDKN2A/2B (10%), EGFR (9.1%), TP53 (8.6%), TERT p (7.4%), PTEN (6.8%). Thirty patients (34%) were oriented to a matched therapy according to actionable alterations, five of them being treated with targeted therapies (BRAF inhibitor; n = 1, EGFR inhibitor; n = 1, mTOR inhibitor; n = 1, FGFR inhibitor; n = 1, TKI-VEGFR n = 1).

Conclusions

Molecular profiling in patients with primary brain tumors is feasible and can lead to orientation in clinical trials and/or treatment with targeted therapies. However the reasons for the small number of patients finally treated are currently under investigations and will be presented at the conference.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Christophe Massard.

Funding

Institut Gustave Roussy.

Disclosure

C. Baldini: Speaker Bureau / Expert testimony: BMS; Speaker Bureau / Expert testimony: Abbvie; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Amgen; Speaker Bureau / Expert testimony: Sanofi. L. Verlingue: Speaker Bureau / Expert testimony: Adaptherapy; Speaker Bureau / Expert testimony: Pierre Fabre; Research grant / Funding (self): BMS. E. Angevin: Advisory / Consultancy: Merck; Advisory / Consultancy: GSK; Advisory / Consultancy: Celgene; Travel / Accommodation / Expenses: Abbvie; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Sanofi; Travel / Accommodation / Expenses: Pfizer. A. Varga: Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: Astra Zeeneca; Speaker Bureau / Expert testimony: MSD. S. Postel Vinay: Research grant / Funding (self): Merck; Research grant / Funding (self): Boehringer; Research grant / Funding (self): Roche; Research grant / Funding (self): AstraZeneca; Speaker Bureau / Expert testimony: Merck; Speaker Bureau / Expert testimony: AstraZeneca; Travel / Accommodation / Expenses: AstraZeneca. A. Gazzah: Travel / Accommodation / Expenses: Boehringer; Travel / Accommodation / Expenses: Novartis; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Novartis. R. Bahleda: Travel / Accommodation / Expenses: Taiho; Travel / Accommodation / Expenses: Janssen; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Boehringer. A. Marabelle: Advisory / Consultancy: Roche; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Onxeo; Advisory / Consultancy: EISAI; Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy: Genticel; Advisory / Consultancy: Rigontec; Advisory / Consultancy: Diachii; Advisory / Consultancy: Imaxio; Advisory / Consultancy: Sanofi; Advisory / Consultancy: BioNtech; Advisory / Consultancy: Corvus; Advisory / Consultancy: Deerfield; Advisory / Consultancy: Bioncotech; Research grant / Funding (self): Merus; Research grant / Funding (self): BMS; Research grant / Funding (self): Boehringer; Research grant / Funding (self): Transgene. V. Ribrag: Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy: Pharmamar; Advisory / Consultancy: Incyte; Advisory / Consultancy: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Nanostring Technologies; Speaker Bureau / Expert testimony: Servier; Honoraria (self): Eisai. S. Champiat: Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: BMS; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: Novartis; Speaker Bureau / Expert testimony: Janssen. J. Michot: Speaker Bureau / Expert testimony: BMS; Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: Janssen. A. Hollebecque: Advisory / Consultancy: Amgen; Advisory / Consultancy: Spectrum Pharmaceuticals; Advisory / Consultancy: Lilly; Travel / Accommodation / Expenses: Servier; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Lilly; Speaker Bureau / Expert testimony: Bayer. J. Soria: Full / Part-time employment: Medimmune. C. Massard: Advisory / Consultancy: Amgen; Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: Beigene; Advisory / Consultancy: BMS; Advisory / Consultancy: Celgene; Advisory / Consultancy: Debiopharm; Advisory / Consultancy: Roche/Genentech; Advisory / Consultancy: Lilly; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Janssen; Advisory / Consultancy: Medimmune; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.